SEC EDGARJUN 52 min read$INSM

Lewis William sold $778K of INSM

Lewis William (Chair and CEO) sold 7,605 shares of INSMED Inc (INSM) at $102.27 ($0.78M total) on 2026-06-03.

Original reporting

SEC EDGAR · Lewis William

Published Jun 5, 2026, 8:12 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 5, 2026, 8:14 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$INSM

Neutral

medium confidence

Mentioned

$INSM

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$INSMNeutralLow

Why it matters

Traders may briefly reassess sentiment around management alignment, but without additional disclosures (guidance, trial results, financing, or legal updates) the impact is likely limited to positioning/flow rather than fundamentals.

Market read

A disclosed insider sale can influence short-term sentiment, but it is not a standalone fundamental catalyst.

What to watch

The filing doesn’t state reasons for the sale, and the post-transaction share count remains sizable, which can mute bearish interpretation.

Relevance 6/10Novelty 6/10Timing: Filed today; reflects sale executed 2026-06-03.

Background

The article is an SEC Form 4 insider transaction disclosure for INSMED Inc, reporting an open-market sale by the CEO/Chair.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INSMNeutralMedium confidence

Context

INSMED CEO/Chair Lewis William sold 7,605 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Low probability of a sustained price move; any reaction is likely short-lived unless accompanied by other news.

Evidence & confidence

The filing is an ownership-change disclosure with no 10b5-1 plan and no accompanying company-specific operational update, limiting causal linkage to fundamentals.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated read-across to peers.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Absence of a 10b5-1 plan doesn’t necessarily signal negative fundamentals; sales can be for diversification, taxes, or planned liquidity needs.

Key entities

issuer
INSMED Inc
Subject of the SEC Form 4 insider sale by its Chair and CEO.
insider
Lewis William
Chair and CEO who sold 7,605 shares at $102.2700 on 2026-06-03.

Read at source ← All news

OCT 22

$INSMMed

Brensocatib Launches in Japan for Non-CF Bronchiectasis

Insmed Inc. launched Brinsupri (brensocatib hydrate) in Japan for non-cystic fibrosis bronchiectasis, following approvals in the U.S. and Europe. The treatment, backed by clinical trial data, is the first of its kind in Japan. Insmed executives highlighted its potential to address unmet medical needs and improve patient outcomes.

ajmc.com3 min

OCT 20

$INSMLow

Insmed Appoints Former Sanofi CEO Paul Hudson and Utpal Koppikar to Board

Insmed Inc. (INSM) added former Sanofi CEO Paul Hudson and Verily Health CFO Utpal Koppikar to its board, enhancing commercial and financial expertise. The company is expanding globally and advancing its drug pipeline. Hudson and Koppikar bring extensive experience in pharmaceutical operations and financial management, respectively.

citybiz.co2 min

OCT 19

$INSMHigh

Insmed launches bronchiectasis treatment in Japan

Insmed Incorporated (INSM) launched BRINSUPRI Tablets 25 mg in Japan for treating non-cystic fibrosis bronchiectasis in adults and pediatric patients 12+. The therapy, approved in August 2026, is the first of its kind in Japan. BRINSUPRI is also approved in the U.S. and EU for similar indications. Common side effects include rash, dry skin, and hypertension. Insmed is a biopharmaceutical company based in New Jersey.

investing.com1 min

OCT 19

$INSMMed

In Japan, patients can now get the only approved treatment for a lung disease that permanently widens airways.

Insmed Inc. announced that BRINSUPRI, the first approved treatment for non-cystic fibrosis bronchiectasis (NCFB), is now available by prescription in Japan. BRINSUPRI is a once-daily oral therapy designed to reduce airway inflammation. The company highlighted the substantial disease burden of NCFB and the need for effective treatments. Insmed also provided details on the drug's safety profile and potential side effects, including dermatologic and gingival adverse reactions.

stocktitan.net2 min

OCT 15

$INSMMedAI 8/10

Insmed launches four phase 3 trials for lung disease therapy

Insmed Inc. (INSM) launched four Phase 3 trials for its lung disease therapy, treprostinil palmitil. The PALM program includes studies for pulmonary arterial hypertension, pulmonary hypertension with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Three trials have started, with the fourth expected in early 2027. The therapy is not yet approved.

investing.com2 min

OCT 14